Trials / Sponsors / Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Industry · 5 registered clinical trials — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Idiopathic Pulmonary Fibrosis | Phase 1 | 2026-03-01 |
| Active Not Recruiting | A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease | Phase 2 | 2024-11-15 |
| Completed | A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects Idiopathic Pulmonary Fibrosis | Phase 1 | 2023-05-03 |
| Completed | A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harbo Solid Tumors With PTCH1 Loss-of-function Mutations | Phase 2 | 2022-05-24 |
| Completed | A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Idiopathic Pulmonary Fibrosis | Phase 2 | 2021-08-26 |